Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting
SHAOXING, China, Oct. 25, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chinese patients with advanced NUT carcinoma (NC). In this multicenter, open-label, single-arm phase II study, patients with advanced NC received oral NHWD-870...
Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026
BEIJING, Oct. 24, 2026 /PRNewswire/ -- Likang Life Sciences ("Likang"), a biotechnology company advancing AI-enabled personalized cancer immunotherapies, sponsored and exhibited at the Abu Dhabi Future Health Summit 2026, held from 20 to 22 October at ADNEC Centre Abu Dhabi. The summit marked a milestone in Likang's international outreach, showcasing its scientific platform and clinical development programs. Convened by...
Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO
CHENGDU, China, Oct. 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, updated results from the Phase II MK-2870-002/SKB264-II-06 study of sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱®) plus MSD's anti-programmed...
19th EU-China Business Meeting Concludes! Third-Generation Triple-Helix Biomimetic Collagen Medical Devices Make Their Global Debut, Highlights from the Event
CHENGDU, China, Oct. 24, 2026 /PRNewswire/ -- At the 19th EU-China Business Meeting, co-hosted by the China Chamber of International Commerce (CCOIC) and the European Union Chamber of Commerce in China (EUCCC) in Chengdu, LivingPHOENIX Regenerative Technology Development (Chengdu) Co., Ltd. (hereinafter referred to as "LivingPHOENIX"), a tenant enterprise of Tianfu International Bio City, achieved a significant milestone....
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology SEOUL, South Korea, Oct. 24, 2026 /PRNewswire/ -- Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment...
Dimora Medical Supports Empower HS 2026, Advancing Everyday Wound Care for the HS Community
- Silicone foam dressings featuring MegaSorb™ technology were included in attendee gift bags to support at-home management of exuding wounds NEW YORK, Oct. 24, 2026 /PRNewswire/ -- Dimora Medical, a pioneer in professional wound care, supported the HS Connect Empower Conference 2026. Taking place on October 16-17 in Houston, Texas, this premier event is dedicated to educating, connecting, and...
Ractigen Therapeutics Publishes Foundational Study on its Extrahepatic LiCO™ Delivery Platform in Molecular Therapy – Nucleic Acids
Peer-reviewed study demonstrates potent, multi-month extrahepatic delivery via both systemic administration—targeting skeletal muscle, heart, and adipose tissue—and localized routes across ocular, joint, and bladder compartments Unlocks high-value therapeutic tissues for neuromuscular, cardiovascular, and cardiometabolic diseases through CD36-mediated uptake, achieving ~90% target knockdown and functional muscle hypertrophy in non-human primates with only transient liver activity Clinically validated across...
Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
- At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate of 81.9% (n=33) in 1L ES-SCLC - Among patients with at least six-months follow-up (n=15) treated at 1.6 mg/kg zoci plus atezolizumab, median progression-free survival and median...
2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS
Registrational Phase 3 G-HOPE-001 Study Met Both Primary Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Overall Survival and Progression-Free Survival Benefits in Previously Treated, CLDN18.2-positive Gastric Cancer Arcotatug Tavatecan Demonstrated a Favorable Safety Profile, with a Low Incidence of Gastrointestinal Adverse Events Arcotatug tavatecan is the First CLDN18.2-ADC to have a New Drug Application Accepted for Regulatory...
Coreline Soft Receives U.S. FDA 510(k) Clearance for AVIEW Aorta Metrics, Expanding Its Chest CT AI Portfolio in the U.S.
Secures its 13th FDA 510(k) clearance, expanding its U.S. portfolio from lung nodule detection and coronary artery calcium (CAC) analysis to quantitative aortic assessment Enables automated aortic segmentation and diameter measurements across anatomical regions, broadening the quantitative capabilities of chest CT Will showcase the AVIEW platform and its U.S. clinical...
